Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Exploring the potential to create ethical psychedelics companies, a DNA test to inform psychedelic therapies, and preparing for the PSYCH Investor Summit: Europe and Asia. Read more in Issue 23 of The Psychedelics Newsletter.
Four companies added to the world’s largest psychedelics exchange and adding Field Trip Health to the PSYCH Investor Summit: Europe and Asia. Learn more in Issue 22 of The Psychedelics Newsletter.
The Australian government has announced $15m of funding for psychedelic medicines in a boost to the domestic and international market. Learn more in Issue 21 of The Psychedelics Newsletter.
The first-ever ketamine-assisted psychotherapy clinic has opened in the UK while Field Trip Health has confirmed the closing of $95m of funding. All this and more in Issue 20 of The Psychedelics Newsletter.
Researchers have published the results of a global drug survey, revealing that the use of psychedelics to treat mental health conditions is increasing.
Researchers have published the results on the most comprehensive study on microdosing while European psychedelic companies have been given an edge in the international market.
The results of a study on the use of MDMA to treat alcohol addiction have been published this week, whilst reforms on the use of psychedelics continue to take shape across the US.
The PSYCH Investor Summit is now open for registration and you can apply for tickets in this week’s issue of our newsletter, which also includes the most important stories from across the industry.
The Psychedelics industry has hit a major milestone as a number of industry-leading businesses have been listed on a dedicated exchange, allowing shares to be traded freely.
PSYCH hits 25,000 subscribers to become industry’s fastest-growing newsletter while a number of major announcements on the advancement of research into psychedelic medicines have been made.
Following a breakout year for the psychedelic sector, the pharmaceutical industry is set to take on a more prominent role in the market in 2021 and beyond. Learn more and catch up with the latest investment trends and scientific findings in Issue 13 of The Psychedelics Newsletter.
The psychedelic compound known as DMT will be used in a trial to treat depression for the first time in the United Kingdom while MDMA has been proven to help people suffering from alcohol addiction. All this and more in issue 12 of the PSYCH Newsletter.
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Subscribe to the Psychedelics Newsletter
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
